Clinical Trial Update: Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) [Phase 3]

View source ↗

Summary

This Phase 3 long-term safety and efficacy study of Lebrikizumab in adults with moderate-to-severe Atopic Dermatitis has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Lebrikizumab (lebrikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2025-08-03